乙肝增强疫苗-长春华普

MP4

A vaccine is a medicine that produces immunity from a particular disease.  Essential to the prevention of sickness and death from infectious diseases, vaccines have led to some of the major public health triumphs of modern medicine, including the global eradication of smallpox and elimination of poliomyelitis and measles from large parts of the world.  Despite this legacy, there are still many challenges in preventing infectious diseases with vaccines.  Examples of these challenges include:
* Developing effective vaccines for specific populations, such as those with a reduced immune response;

* Developing vaccines for more effective protections against certain lethal viral infections;

* Developing vaccines that require less frequent administration, thus improving compliance, which is critical for the complete protection by those vaccines requiring multiple immunizations;

* The need for rapid large scale production, which might be necessary in a public health emergency, to protect as many people as possible.

Adjuvants, which are pharmacological agents added to a vaccine to increase or aid its effectiveness, can be used to address these challenges.  Huapu Bio is developing proprietary, molecularly designed adjuvants that are TLR9 agonists (CpG ODN adjuvants), and has obtained preclinical proof of concept suggesting that its novel, next generation adjuvants offer an enhanced quality of the immune response that can potentially:

* Improve immune responses in poorly responsive populations to a hepatitis B vaccine, such as the elderly and/or the immunocompromised;

* Enhance vaccine protection by inducing an earlier and higher level production of neutralizing antibody against the virus that causes rabies, a human disease that is almost always fatal in 100% of cases;

* Improve compliance by requiring less frequent administration of vaccines for both HBV and rabies;

* Reduce the amount of antigen needed in an influenza vaccine, enabling an increase in the manufacturing capacity during a pandemic.

Huapu Bio has formed a partnership with Walvax to codevelop a TLR9 agonist-adjuvanted vaccine for  hepatitis B.   In June, 2013, Huapu Bio and Walvax received clinical trial approval for hepatitis B vaccine (CpG ODN adjuvant) from the China Food and Drug Administration.  



长春华普生物技术有限公司 华普生物医药(上海)有限公司

http://d2012.this-is-a-demo-website-just-for-testing-purpose-only.info/manager.aspx?m=20131126134519903032&t=2


沃森生物